More transparency in studies
06.12.2012 11:07
Two portals are intended to ensure more transparency in clinical studies. One portal - www.pharmnet-bund.de - was launched by the BMG, another - www.patient-registry.com - by a private provider from Austria.
In the portal PharmNet.Bund (www.pharmnet-bund.de) you can now find information about clinical drug trials approved in Germany. “Everyone can view the data on clinical studies free of charge,” explained Federal Health Minister Daniel Bahr on the occasion of the launch of the new database for clinical trials, which – according to Bahr – is intended to create “transparency for doctors, patients and other interested citizens”. The database contains extensive data sets on clinical trials from August 2004. This includes, among other things, information about the sponsor (natural or legal person responsible for the trial), the design (structure, division into trial centers, duration, etc.), and the drug to be tested/tested as well as areas of application, objectives and test phases and people who should be included in the test.
In order to offer interested parties and potential initiators information and services, the Austrian company asoluto has the website www.patient-registry.com launched, which provides an overview of the possibilities, the success criteria and the organizational structures and processes of clinical patient registries. The patient registry platform was developed by asoluto in cooperation with OeKB-Business Services (OeKB-BS). All data is stored on fail-safe servers in the Oesterreichische Steuerbank AG (OeKB) data centers, which are protected from unauthorized access using the most modern security mechanisms. The team at the communications agency asoluto public + interactive relations started operating the first clinical patient register in 2002. Today, according to the company's own statements, the national and multinational solutions developed since then, such as the Austrian CML Register, are considered a benchmark in the scientific community.